This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Chiron Buying Matrix Pharmaceutical

Chiron (CHIR) said Monday that it is acquiring Matrix Pharmaceutical (MATX - Get Report) for $61 million in cash to expand its portfolio of early-stage experimental cancer drugs.

Wall Street has been expecting Chiron to make an acquisition because the Emeryville, Calif.-based biopharmaceutical firm is in desperate need of strengthening its drug pipeline after the failure in November of its experimental sepsis drug. U.S. drug regulators have also delayed the approval of Chiron's NAT blood-testing system, which was supposed to happen by the end of 2001, according to the company.

Whether the purchase of Matrix helps Chiron's growth story remains unclear. Matrix is still recovering from a major setback in September when an FDA advisory panel voted against its experimental head and neck cancer treatment, IntraDose. Matrix continues to pursue the drug's approval in Europe.

But Chiron seems more interested in another early-stage cancer drug, tezacitabine, that Matrix is developing. Matrix just started Phase 2, or mid-stage, testing of the drug in patients with solid tumors. Once it acquires Matrix, Chiron says it will continue this testing program.

Chiron says it expects to close the Matrix deal in the first quarter. The boards of both companies have approved the merger. The $61 million deal values Matrix at $2.30 a share, based on the 25.6 million Matrix shares outstanding.

Matrix shares were falling nearly 16% in recent trading to $2.18. Chiron shares were lower as well, off 72 cents, or 1.6%, to $44.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
MATX $42.37 0.00%
AAPL $130.28 0.00%
FB $81.53 0.00%
GOOG $565.06 0.00%
TSLA $218.42 0.00%

Markets

DOW 18,080.14 +21.45 0.12%
S&P 500 2,117.69 +4.76 0.23%
NASDAQ 5,092.0850 +36.0220 0.71%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs